Clinical trials of selective BRAF inhibitors have shown dramatic results among melanoma patients whose tumors possess BRAFV600E mutation, but not those without the mutation, highlighting the potential clinical importance of genotyping patients' tumors to select the appropriate treatment [12], [13], [14], [15]. The gene discussed is BRAF; the disease is melanoma.